Efficacy and safety of bictegravir plus lenacapavir: 48-week outcomes in virologically suppressed people with HIV-1 on complex antiretroviral regimens at baseline

被引：0
|
作者：
Mounzer, K. [1 ]
Slim, J. [2 ]
Ramgopal, M. [3 ]
Hedgcock, M. [4 ]
Bloch, M. [5 ]
Santana, J. [6 ]
Mendes, I. [7 ]
Zhang, X. [7 ]
Sklar, P. [7 ]
Montezuma-Rusca, J. M. [7 ]
Segal-Maurer, S. [8 ]
机构：
[1] Philadelphia FIGHT, Philadelphia, PA USA
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Midway Immunol & Res Ctr, Ft Pierce, FL USA
[4] Spectrum Hlth, Vancouver, BC, Canada
[5] Holdsworth House Med Practice, Darlinghurst, NSW, Australia
[6] Univ Puerto Rico, San Juan, PR 00936 USA
[7] Gilead Sci Inc, Foster City, CA 94404 USA
[8] New York Presbyterian Queens, Flushing, NY USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OAB2602
引用
收藏
页码：16 / 16
页数：1
相关论文
共 50 条
  • [1] Metabolic changes at 48 weeks in virologically suppressed people with HIV switching from complex antiretroviral regimens to bictegravir plus lenacapavir: ARTISTRY-1 trial
    Prelutsky, David
    Mounzer, Karam
    Ramgopal, Moti
    Slim, Jihad
    Hedgcock, Malcolm
    Segal-Maurer, Sorana
    Bloch, Mark
    Zhang, Xu
    Montezuma-Rusca, Jairo M.
    Sklar, Peter
    Ruane, Peter
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 59 - 60
  • [2] Switching to bictegravir/ emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviralexperienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis
    Podzamczer, D.
    Imaz, A.
    Lopez-Lirola, A.
    Knobel, H.
    Masia, M.
    Fanciulli, C.
    Hernadez, C.
    Lagarde, M.
    Gutierrez, A.
    Curran, A.
    Morano, L.
    Montero-Alonso, M.
    Troya, J.
    Rigo, R.
    Casadella, M.
    Navarro-Alcaraz, A.
    Ardila, F.
    Parera, M.
    Bernal, E.
    Echeverria, P.
    Estrada, V.
    Hidalgo-Tenorio, C.
    Macias, J.
    Priet, P.
    Portilla, J.
    Valencia, E.
    Vivancos, M. J.
    Rivero, A.
    HIV MEDICINE, 2023, 24 : 310 - 311
  • [3] Efficacy and safety of switching to dolutegravir/lamivudine by baseline regimen in virologically suppressed adults: 48-week pooled analysis
    Scholten, Stefan
    Cahn, Pedro
    Ruane, Peter
    Kaplan, Richard
    Portilla, Joaquin
    Hodder, Sally
    Bisshop, Fiona
    Wynne, Brian R.
    Grove, Richard
    Bontempo, Gilda
    Moodley, Riya
    Jones, Bryn
    Ait-Khaled, Mounir
    Okoli, Chinyere
    Fetscher, Harald
    HIV MEDICINE, 2023, 24 : 24 - 25
  • [4] Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
    Duenas-Gutierrez, Carlos
    Buzon, Luis
    Pedrero-Tome, Roberto
    Iribarren, Jose A.
    De los Santos, Ignacio
    De la Fuente, Sara
    Pousada, Guillermo
    Moran, Miguel Angel
    Moreno, Estela
    Ferreira, Eva
    Gomez, Julia
    Troya, Jesus
    VIRUSES-BASEL, 2023, 15 (04):
  • [5] Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand
    Phongsamart, Wanatpreeya
    Jantarabenjakul, Watsamon
    Chantaratin, Sasitorn
    Anugulruengkitt, Suvaporn
    Suntarattiwong, Piyarat
    Sirikutt, Pakpen
    Kosalaraksa, Pope
    Maleesatharn, Alan
    Chokephaibulkit, Kulkanya
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 (01)
  • [6] Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
    Troya, Jesus
    Montejano, Rocio
    Ryan, Pablo
    Gomez, Cristina
    Matarranz, Mariano
    Cabello, Alfonso
    Vera, Francisco
    Antonia Sepulveda, Maria
    Santos, Ignacio
    Samperiz, Gloria
    Bachiller, Pablo
    Boix, Vicente
    Barrufet, Pilar
    Cervero, Miguel
    Sanz, Jose
    Solis, Javier
    Yllescas, Maria
    Valencia, Eulalia
    PLOS ONE, 2018, 13 (06):
  • [7] SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
    Campo, R.
    DeJesus, E.
    Bredeek, U. F.
    Henry, K.
    Khanlou, H.
    Logue, K.
    Brinson, C.
    Benson, P.
    Dau, L.
    Wang, H.
    White, K.
    Flaherty, J.
    Fralich, T.
    Guyer, B.
    Piontkowsky, D.
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (11) : 1637 - 1645
  • [8] Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
    Scholten, Stefan
    Cahn, Pedro
    Portilla, Joaquin
    Bisshop, Fiona
    Hodder, Sally
    Ruane, Peter
    Kaplan, Richard
    Wynne, Brian R.
    Man, Choy Y.
    Grove, Richard
    Wang, Ruolan
    Jones, Bryn
    Ait-Khaled, Mounir
    Kisare, Michelle
    Okoli, Chinyere
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (07):
  • [9] Comparability of 48-week efficacy and safety of cabotegravir plus rilpivirine long-acting every 8 weeks to standard of care in patients with suppressed HIV-1
    Chounta, V.
    Snedecor, S.
    Van de Velde, N.
    HIV MEDICINE, 2020, 21 : 28 - 29
  • [10] Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
    Sharon Walmsley
    Don E. Smith
    Miguel Górgolas
    Pedro E. Cahn
    Thomas Lutz
    Karine Lacombe
    Princy N. Kumar
    Brian Wynne
    Richard Grove
    Gilda Bontempo
    Riya Moodley
    Chinyere Okoli
    Michelle Kisare
    Bryn Jones
    Andrew Clark
    Mounir Ait-Khaled
    AIDS Research and Therapy, 21
12345